{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:09:45Z","timestamp":1790197785236,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Background: Alcohol Use Disorder (AUD) is a major contributor to global morbidity, mortality, and socioeconomic burden. Cravings, defined as intense urges to consume alcohol, play a central role in relapse and are recognized as a diagnostic criterion in DSM-5. Pharmacological strategies targeting cravings may offer immediate or short-term relief, complementing existing long-term approaches. However, evidence on short-term (up to approximately three months) anti-craving interventions remains fragmented. Objective: To systematically review randomized, double-blind, placebo-controlled trials (RCTs) assessing the short-term effects of pharmacological treatments on cue-induced alcohol cravings. Methods: A systematic search was conducted in PubMed and PsycINFO using terms related to alcohol, craving, and randomized controlled designs. Eligibility included clinical trials on alcohol-dependent participants that evaluated craving as an outcome. Exclusion criteria encompassed non-clinical studies, non-pharmacological interventions, animal studies, single-blind trials, and studies with psychiatric comorbidities. Study quality was appraised using Cochrane and Joanna Briggs Institute tools. Results: From 442 studies screened, 26 RCTs fulfilled the inclusion criteria. In total, 1097 participants were enrolled across the trials (range = 16\u2013125 per study; mean = 44), predominantly male outpatients aged 15\u201365 years. Craving was assessed primarily with the Visual Analog Scale and Alcohol Urge Questionnaire. Intervention duration ranged from 1 to 98 days. Naltrexone consistently reduced cue-induced craving across four trials, with additional benefit observed when combined with ondansetron. Varenicline and acamprosate also demonstrated reductions in craving and drinking. Memantine showed efficacy in craving reduction but was not assessed for abstinence. Topiramate was effective, whereas gabapentin showed limited short-term benefit. Other agents (e.g., citalopram, oxytocin, ondansetron, quetiapine) yielded mixed findings, often limited to single studies. Overall, 58% of trials reported positive anti-craving effects, 23% no difference, and 8% increased craving versus placebo. However, these findings should be interpreted in light of important methodological limitations, including small sample sizes and heterogeneous experimental paradigms. Conclusions: This review suggests that naltrexone and varenicline appear to be the most consistently supported short-term pharmacotherapies for alcohol craving within the available evidence, with promising but less consistent findings for memantine, acamprosate, and topiramate. These results highlight potential candidates for immediate craving management in AUD, while underscoring the need for larger and longer-term trials to confirm their efficacy and safety.<\/jats:p>","DOI":"10.3390\/medicines13010007","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:55:47Z","timestamp":1771253747000},"page":"7","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacotherapy for Alcohol Craving Reduction: Efficacy of Short-Term Treatments in Alcohol Use Disorder"],"prefix":"10.3390","volume":"13","author":[{"given":"Matheus","family":"Cheibub David Marin","sequence":"first","affiliation":[{"name":"Perdizes Institute (IPer), Clinics Hospital of the Medical School (HCFMUSP), University of S\u00e3o Paulo, S\u00e3o Paulo 05021-001, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-093X","authenticated-orcid":false,"given":"Maria Olivia","family":"Pozzolo Pedro","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo 05403-903, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3893-1743","authenticated-orcid":false,"given":"Giuliana","family":"Perrotte","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo 05403-903, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9621-2291","authenticated-orcid":false,"given":"Jo\u00e3o Mauricio","family":"Castaldelli-Maia","sequence":"additional","affiliation":[{"name":"Perdizes Institute (IPer), Clinics Hospital of the Medical School (HCFMUSP), University of S\u00e3o Paulo, S\u00e3o Paulo 05021-001, Brazil"},{"name":"Department of Psychiatry, Medical School, University of S\u00e3o Paulo, S\u00e3o Paulo 05403-903, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1176\/appi.ajp.2018.17101174","article-title":"Neuroscience of addiction: Relevance to prevention and treatment","volume":"175","author":"Volkow","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"key":"ref_4","unstructured":"Pan American Health Organization\u2014WHO Americas Region (2024, July 20). Alcohol. Available online: https:\/\/www.paho.org\/en\/topics\/alcohol."},{"key":"ref_5","unstructured":"World Health Organization (2024, July 20). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/alcohol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.15288\/qjsa.1952.13.673","article-title":"Phases in the drinking history of alcoholics","volume":"13","author":"Jellinek","year":"1952","journal-title":"Q. J. Stud. Alcohol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1300\/J069v20n03_07","article-title":"The measurement of craving","volume":"20","author":"Mezinskis","year":"2001","journal-title":"J. Addict. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0971-6866.132750","article-title":"Neurotransmitters in Alcoholism: A Review of Neurobiological and Genetic Studies","volume":"20","author":"Banerjee","year":"2014","journal-title":"Indian J. Hum. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_10","unstructured":"United Nations International Drug Control Programme and World Health Organization (1992). Informal Expert Committee on Drug-Craving Mechanism, United Nations International Drug Control Programme and World Health Organization. Report No. V. 92-54439 T."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Marin, M.C.D., Pedro, M.O.P., Perrotte, G., Martins-da-Silva, A.S., Lassi, D.L.S., Blaas, I.K., Castaldelli, F.I., Brisola Dos Santos, M.B., Kortas, G.T., and Campos, M.W. (2023). Pharmacological Treatment of Alcohol Cravings. Brain Sci., 13.","DOI":"10.3390\/brainsci13081206"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/13556210500223504","article-title":"A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan","volume":"10","author":"Huang","year":"2005","journal-title":"Addict. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000083037","article-title":"Pharmacological relapse prevention of alcoholism: Clinical predictors of outcome","volume":"11","author":"Kiefer","year":"2005","journal-title":"Eur. Addict. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: A randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_17","unstructured":"Cochrane Consumers and Communication Review Group (2013). Study Quality Guide, La Trobe University. Available online: https:\/\/cccrg.cochrane.org."},{"key":"ref_18","unstructured":"Joanna Briggs Institute (2020). Checklist for Randomized Controlled Trials: Critical Appraisal Tools for Use in JBI Systematic Reviews, Joanna Briggs Institute. Available online: https:\/\/jbi.global\/critical-appraisal-tools."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/npp.2011.192","article-title":"Pharmacogenetics of naltrexone in asian americans: A randomized placebo-controlled laboratory study","volume":"37","author":"Ray","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/acer.14001","article-title":"The Interplay Between Subjective Response to Alcohol, Craving, and Alcohol Self-Administration in the Human Laboratory","volume":"43","author":"Green","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/adb.12050","article-title":"Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: An initial randomized trial","volume":"19","author":"Miranda","year":"2014","journal-title":"Addict. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archpsyc.65.4.466","article-title":"Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people","volume":"65","author":"Myrick","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00213-009-1515-6","article-title":"The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: A randomized controlled trial","volume":"205","author":"Hammarberg","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1176\/ajp.2007.164.3.519","article-title":"Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients","volume":"164","author":"Krupitsky","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00213-003-1617-5","article-title":"Acute effects of memantine in combination with alcohol in moderate drinkers","volume":"172","author":"Bisaga","year":"2004","journal-title":"Psychopharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/alcalc\/agx108","article-title":"Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study","volume":"53","author":"Goodyear","year":"2018","journal-title":"Alcohol Alcohol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1530-0277.2006.00299.x","article-title":"A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm","volume":"31","author":"Myrick","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1007\/s00213-017-4667-9","article-title":"Effects of varenicline on alcohol cue reactivity in heavy drinkers","volume":"234","author":"Roberts","year":"2017","journal-title":"Psychopharmacology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/ADM.0000000000000208","article-title":"Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers with Alcohol Use Disorders","volume":"10","author":"Verplaetse","year":"2016","journal-title":"J. Addict. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biopsych.2009.01.029","article-title":"Varenicline reduces alcohol self-administration in heavy-drinking smokers","volume":"66","author":"McKee","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1530-0277.2008.00783.x","article-title":"Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control","volume":"32","author":"Voronin","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-011-2287-3","article-title":"A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving","volume":"217","author":"Ray","year":"2011","journal-title":"Psychopharmacology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1530-0277.1993.tb00755.x","article-title":"Effect of haloperidol on measures of craving and impaired control in alcoholic subjects","volume":"17","author":"Modell","year":"1993","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/clpt.1992.85","article-title":"Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers","volume":"51","author":"Naranjo","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/archpsyc.55.4.354","article-title":"Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics","volume":"55","author":"Krystal","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/15622975.2013.812239","article-title":"Pharmacological challenge with naloxone and cue exposure in alcohol dependence: Results of a randomized, double-blind placebo-controlled trial","volume":"14","author":"Lieb","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/ADM.0000000000000213","article-title":"Intranasal Oxytocin Selectively Modulates Social Perception, Craving, and Approach Behavior in Subjects with Alcohol Use Disorder","volume":"10","author":"Mitchell","year":"2016","journal-title":"J. Addict. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1038\/tp.2015.140","article-title":"Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving","volume":"5","author":"Aoun","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2014.03.019","article-title":"Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: A preliminary investigation","volume":"76","author":"Leggio","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"pyw048","DOI":"10.1093\/ijnp\/pyw048","article-title":"Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals","volume":"19","author":"Giovenco","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_41","first-page":"969","article-title":"The effect of tryptophan depletion on alcohol self-administration in non-treatment-seeking alcoholic individuals","volume":"26","author":"Petrakis","year":"2002","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_42","first-page":"1151","article-title":"Effect of tryptophan depletion on alcohol cue-induced craving in abstinent alcoholic patients","volume":"25","author":"Petrakis","year":"2001","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-011-2199-2","article-title":"A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects","volume":"216","author":"Watson","year":"2011","journal-title":"Psychopharmacology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1007\/s00213-019-05205-3","article-title":"Targeting neuroinflammation with minocycline in heavy drinkers","volume":"236","author":"Petrakis","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Evenseth, L.S.M., Gabrielsen, M., and Sylte, I. (2020). The GABAB Receptor-Structure, Ligand Binding and Drug Development. Molecules, 25.","DOI":"10.3390\/molecules25133093"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuropharm.2018.01.036","article-title":"GABAA receptor: Positive and negative allosteric modulators","volume":"136","author":"Olsen","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/17425251003641975","article-title":"Acamprosate","volume":"6","author":"Kennedy","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40263-015-0240-4","article-title":"Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders","volume":"29","author":"Hammond","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2174\/156802609789630938","article-title":"Sugar sulfamates for seizure control: Discovery and development of topiramate, a structurally unique antiepileptic drug","volume":"9","author":"Maryanoff","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0920-1211(00)00118-2","article-title":"A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat","volume":"40","author":"Stringer","year":"2000","journal-title":"Epilepsy Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/phrs.1997.0124","article-title":"A pharmacological and clinical review on topiramate, a new antiepileptic drug","volume":"35","author":"Perucca","year":"1997","journal-title":"Pharmacol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/acer.12854","article-title":"Varenicline for treatment of alcohol dependence: A randomized, placebo-controlled trial","volume":"39","author":"Walther","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"7","author":"Litten","year":"2013","journal-title":"J. Addict. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1176\/appi.ajp.20220821","article-title":"Naltrexone and Alcohol Use","volume":"179","author":"Avery","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s43678-023-00448-8","article-title":"Incorporating ondansetron and baclofen in alcohol use disorder treatment","volume":"25","author":"Ross","year":"2023","journal-title":"Can. J. Emerg. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Phimarn, W., Sakhancord, R., Paitoon, P., Saramunee, K., and Sungthong, B. (2023). Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20054091"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"110409","DOI":"10.1016\/j.pnpbp.2021.110409","article-title":"Mechanistic insights into the efficacy of memantine in treating certain drug addictions","volume":"111","author":"Montemitro","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1176\/appi.ajp.20230666","article-title":"Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial","volume":"181","author":"Morley","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients with Alcohol Withdrawal Symptoms: A Randomized Clinical Trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5663274","DOI":"10.1155\/2022\/5663274","article-title":"The Effects of Citalopram and Thalamic Dopamine D2\/3 Receptor Availability on Decision-Making and Loss Aversion in Alcohol Dependence","volume":"2022","author":"Zorick","year":"2022","journal-title":"Psychiatry J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"104605","DOI":"10.1016\/j.psyneuen.2020.104605","article-title":"Intranasal oxytocin as a potential therapeutic strategy in post-traumatic stress disorder: A systematic review","volume":"115","author":"Giovanna","year":"2020","journal-title":"Psychoneuroendocrinology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/bs.irn.2024.07.006","article-title":"Ghrelin system and GLP-1 as potential treatment targets for alcohol use disorder","volume":"178","author":"Jerlhag","year":"2024","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_66","unstructured":"Stokes, M., Patel, P., and Abdijadid, S. (2024, September 10). Disulfiram, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459340\/."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Mandaji, J.V.G., Pozzolo Pedro, M.O., Leopoldo, K., Pini Alemar, J., Torales, J., Ventriglio, A., and Castaldelli-Maia, J.M. (2025). Combination of Drugs in the Treatment of Alcohol Use Disorder: A Meta-Analysis and Meta-Regression Study. Brain Sci., 15.","DOI":"10.3390\/brainsci15060542"},{"key":"ref_68","unstructured":"Mar, Y., Whitley, S.D., Weigand, T.J., Stancliff, S.L., Gonzalez, C.J., and Hoffmann, C.J. (2023). Treatment of Alcohol Use Disorder, Johns Hopkins University."}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/13\/1\/7\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:16:31Z","timestamp":1771254991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/13\/1\/7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medicines13010007"],"URL":"https:\/\/doi.org\/10.3390\/medicines13010007","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}